CDK4/6 inhibitors in breast cancer therapy: Current practice and future opportunities
Author:
Funder
U.S. Food and Drug Administration
Publisher
Elsevier BV
Subject
Pharmacology (medical),Pharmacology
Reference84 articles.
1. Targeting the cyclin-dependent kinases (CDK) 4/6 in estrogen receptor-positive breast cancers;aFinn;Breast Cancer Research,2016
2. A systematic screen for CDK4/6 substrates links FOXM1 phosphorylation to senescense suppression in cancer cells;Anders;Cancer Cell,2011
3. Ribociclib+ letrozole for first-line treatment of HR+, HER2− advanced breast cancer: Efficacy by baseline tumor markers;Andre,2017
4. Single-cell dynamics determines response to CDK4/6 inhibition in triple-negative breast cancer;Asghar;Clinical Cancer Research,2017
5. Hormonoresistance in advanced breast cancer: A new revolution in endocrine therapy;Augereau;Therapeutic Advances in Medical Oncology,2017
Cited by 54 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. SLC7A11 protects luminal A breast cancer cells against ferroptosis induced by CDK4/6 inhibitors;Redox Biology;2024-10
2. Tumor-intrinsic CDC42BPB confers resistance to anti-PD-1 immune checkpoint blockade in breast cancer;Molecular Therapy;2024-07
3. Systematic annotation of orphan RNAs reveals blood-accessible molecular barcodes of cancer identity and cancer-emergent oncogenic drivers;2024-03-21
4. Multicomponent reactions for the synthesis of tetrazole derivatives: Discovery and validation of a novel anticancer agent active against ER positive cancers;Results in Chemistry;2024-01
5. The anticancer potential of chemical constituents of Moringa oleifera targeting CDK-2 inhibition in estrogen receptor positive breast cancer using in-silico and in vitro approches;BMC Complementary Medicine and Therapies;2023-11-04
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3